SCHEMBL2177188

SCHEMBL2177188

O=C(O)CCC(=O)C(=O)OCO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 4/20 0.48
MAPK1 P28482 1/20 0.48
SLC13A3 Q8WWT9 1/20 0.48
OR51E2 Q9H255 1/20 0.48
LMNA P02545 6/20 0.45
ALKBH5 Q6P6C2 1/20 0.45
SUCNR1 Q9BXA5 1/20 0.45
SLC15A2 Q16348 1/20 0.36
CAMK2A Q9UQM7 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.35
KDM5C P41229 3/20 0.33
PHF8 Q9UPP1 3/20 0.33
KDM2A Q9Y2K7 3/20 0.33
KDM6B O15054 2/20 0.33
KDM4E B2RXH2 2/20 0.33
TSHR P16473 2/20 0.33
FOLH1 Q04609 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
NFKB1 P19838 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2402800 0.82 EGLN1 (0.50) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL118022 0.78 FAAH (0.47) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL3682948 0.76 EGLN1 (0.55) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL4445881 0.75 FFAR3 (0.44) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL125702 0.74 EGLN1 (0.52) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL1237232 0.74 LMNA (0.50) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL9668021 0.72 EGLN1 (0.50) EGLN1MAPK1SLC13A3OR51E2LMNA
SCHEMBL28443284 0.72 EGLN1 (0.50) EGLN1MAPK1SLC13A3OR51E2LMNA
Succinic Acid SCHEMBL1462994 0.71
Succinic Acid SCHEMBL17611021 0.71 LMNA (0.90) EGLN1MAPK1SLC13A3OR51E2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120322906-A1 POLYMER AND METHODS OF PREPARING AND USING A POLYMER CARGILL, INCORPORATED (US) 2012-12-20 US disclosed
WO-2012166406-A1 INCREASING PRODUCT YIELD AND/OR THROUGHPUT BY SUPERSATURATION OF SUBSTRATE CARGILL, INCORPORATED (US) 2012-12-06 WO disclosed
WO-2012166842-A1 INCREASING PRODUCT YIELD AND/OR THROUGHPUT BY SUPERSATURATION OF SUBSTRATE CARGILL, INCORPORATED (US) 2012-12-06 WO disclosed
EP-2519406-A1 A POLYMER AND METHODS OF PREPARING AND USING A POLYMER Cargill, Incorporated (US) 2012-11-07 EP disclosed
US-20120270281-A1 BIOREACTOR PERFORMANCE IN THE PRODUCTION OF MONATIN CARGILL, INCORPORATED (US) 2012-10-25 US disclosed
US-20120264948-A1 MEMBRANE SEPARATION AND PURIFICATION OF MONATIN CARGILL, INCORPORATED (US) 2012-10-18 US disclosed
CN-102686391-A A polymer and methods of preparing and using a polymer CARGILL INC 2012-09-19 CN disclosed
WO-2011082365-A2 IMPROVED BIOREACTOR PERFORMANCE IN THE PRODUCTION OF MONATIN CARGILL, INCORPORATED (US) 2011-07-07 WO disclosed
WO-2011082353-A1 SEPARATION AND PURIFICATION OF MONATIN CARGILL, INCORPORATED (US) 2011-07-07 WO disclosed
WO-2011082363-A1 MEMBRANE SEPARATION AND PURIFICATION OF MONATIN CARGILL, INCORPORATED (US) 2011-07-07 WO disclosed
WO-2011082351-A1 A POLYMER AND METHODS OF PREPARING AND USING A POLYMER CARGILL, INCORPORATED (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264948-A1 MEMBRANE SEPARATION AND PURIFICATION OF MONATIN MON2, STOM, MLEC EGLN1 4766/4885MAPK1 4405/4885SLC13A3 431/4885
US-20120322906-A1 POLYMER AND METHODS OF PREPARING AND USING A POLYMER MON2, STOM, LCP1 EGLN1 3704/4885MAPK1 2443/4885SLC13A3 2555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.